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INTRODUCTION 
 Fast Drug Delivery Systems are rapidly gaining interest in the 
pharmaceutical industry. These systems either dissolve or disintegrate generally 
within a minute without needing water or chewing. These systems offer superior 
clinical profiles with potentional oro mucosal absorption thus increasing the drug 
bioavailability with respect to oral administration. Recently thin films have been 
proposed which rapidly dissolves or disintegrates into buccal cavity. Mouth 
dissolving films are novel dosage forms that disintegrate or dissolve in the oral 
cavity. These are ultra thin postage stamp size with an active agent or 
pharmaceutical excipients. These dosage forms are placed on the tongue or any 
mucosal tissue. When wet with saliva, the films rapidly hydrates and adheres on to 
the site of application. It rapidly dissolves or disintegrates to release the medicine 
for mucosal absorption or with modification, allows for oral GIT absorption with 
quick dissolving properties.  
 An important benefit of these dosage forms is accurate dosing as compared 
to liquid dosage form, no water is needed and there is no fear of choking as 
compared to tablets and capsules. After disintegrating in the mouth, enhanced the 
clinical effect of drug through pre-gastric absorption from mouth pharynx and 
esophagus as the saliva passes down into the stomach. In such cases, 
bioavailability of drug is significantly greater than those observed from 
conventional tablet dosage form. More recently, Fast-dissolving buccal film drug 
delivery systems have rapidly gained acceptance as an important new way of 
administering drugs. They are usually used for pharmaceutical and nutraceuticals 
products. It is the newest frontier in drug delivery technology that provides a very 
convenient means of taking medications and supplements. Fast dissolving films 
are also applicable when local action in the mouth is desirable such as local 
anesthetic for toothaches, oral ulcers, cold sores, or teething  
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 Oral route is the most preferred route of administration for systemic effect. 
About 60% of all formulations are of solid dosage form. Tablet is the most 
preferred dosage form due to ease of transportation, manufacturing and more 
patient compliance. Generally pediatric geriatric and forbidden patients 
experience difficulties in swallowing the conventional tablet. To overcome this 
problem a novel formulation was developed .i.e. oral fast dissolving films 
(Siddiquinehal et al., 2011) . 
FDF is prepared using hydrophilic polymers that rapidly dissolves on the 
tongue or buccal cavity, delivering the drug to the systemic circulation via buccal 
mucosa. (Mahajan AN et al.,2011). The fast dissolving drug delivery system are 
specially designed for the drugs which have extensive first pass metabolism and 
have low dose, for the enhancement of bioavailability. (Suresh B 2006). 
Special features of Mouth dissolving films (Suresh et al.,2006) 
 Thin elegant film 
 Available in various size and shape 
 Unobstructive 
 Excellent mucoadhesion 
 Fast disintegration 
 Rapid release 
Advantages of fast dissolving films(Bhura et al.,2012) 
 Convenient dosing. 
 No water needed. 
 No risk of chocking 
 Taste masking. 
 Enhanced stability. 
Introduction 
 
 
 
Department of Pharmaceutics 3 
 Improved patient compliance. 
 The drug enters the systemic circulation with reduced hepatic first  pass 
 effect. 
 Site specific and local action. 
 Availability of large surface area that leads to rapid disintegration and 
dissolution within oral cavity. 
 Dose accuracy in comparison to syrup.  
Disadvantages 
 High doses cannot be incorporated. 
 Dose uniformity is a technical challenge 
 Hygroscopic in nature 
 Require special packaging for products 
 Stability and safety 
 
Development of Oral Solid Dosage Form:  
Various stages of development of the of oral solid dosage formulation 
Simple conventional oral solid dosage forms(tablets,capsules) 
 
Modified release tablets/capsules 
 
Fast dissolving tablets/capsules 
 
Wafer to recent fast dissolving oral film 
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Overview of Oral Mucosa: 
The oral mucosa is composed of an outermost layer of stratified squamous 
epithelium. Below this lies a basement membrane, a lamina propria followed by 
the sub mucosa as the innermost layer. The epitheliumis similar to stratified 
squamous epithelia found in the rest of the body in that it has a mitotic ally active 
basal cell layer, advancing through a number of Differentiating intermediate 
layers to the superficial layers, where cells are shed from the surface of the 
epithelium. 
 
 
 
 
 
Figure 1: overview of oral mucosa 
Ideal characteristics of suitable drug candidate (arya et al.,2010) 
 The drug should have pleasant taste. 
 The drug to be incorporated have low dose up to 40 mg. 
 The drugs with smaller and moderate molecular weight are preferable. 
 The drug should have good stability and solubility in water as well  as in 
 saliva. 
 It should be partially unionized at the pH of oral cavity. 
 It should have the ability to permeate oral mucosal tissue 
 
Classifications of Fast Dissolve Technology  
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Fast-dissolve technologies can be divided in to three broad groups 
 Lyophilized systems 
 Compressed tablet-based systems 
 Oral thin film 
1.  The lyophilized systems 
This technology involves taking a suspension or solution of drug with 
other structural excipients, by using mould or blister pack, which forms tablet-
shaped units. The units or tablets are then frozen and lyophilized in the pack or 
mould. The resulting units are of very high porosity, which allows rapid water or 
saliva penetration and very rapid disintegration. 
 2.  Compressed tablet-based systems 
The standard tablet technology by direct compression of excipients is used 
to produce this system. The tablet technologies have different levels of hardness 
and friability depending on the method of manufacture. The speed of 
disintegration for fast-dissolve tablets compared with a standard tablet is achieved 
by formulating it using water soluble excipients, super-disintegrant or effervescent 
components, to allow rapid penetration of water into the core of the tablet. 
3.  Oral thin film (Aggarwal et al., 2011) 
It is also called as oral wafers. From the past few years the oral thin films 
are evolved in confection and oral care markets in the form of breath strips. These 
are novel and widely accepted form by consumers for delivering vitamins and 
personal care products. Such systems use a variety of hydrophilic polymers to 
produce a 50- 200 mm film.  
 
Classification of Oral thin film 
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Following are the subtypes of oral fast dissolving films: 
 Flash release. 
  Mucoadhesive melt-away wafer. 
METHOD OF PREPARATION OF MOUTH DISSOLVING FILMS 
(Mahajan A et al., 2011 ) 
 One or a combination of the following processes can be used to 
manufacture the Mouth Dissolving film: 
 Solvent casting method 
 Hot-melt extrusion 
 Semisolid casting 
 Solid dispersion extrusion 
 Rolling 
 
1.  Solvent casting method 
Water soluble ingredients are dissolved in water 
 
API and other agents are dissolved in suitable solvent 
to form a clear viscous solution 
 
Both the solutions are mixed 
 
Degassed under vacuum 
 
Resulting solution is cast as a film 
Advantage: 
Introduction 
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 Great uniformity of thickness and great clarity than extrusion 
 Films have fine gloss & freedom from defect such a die liners 
 Films have more flexibility & better physical properties 
Disadvantage: 
 Polymer must be soluble in volatile solvent or water 
 The stable solution with reasonable minimum solid content 
 
2.  Hot melt extrustion 
 
The drug is mixed with carriers in solid form 
 
Extruder having heaters melts the mixture 
 
Finally the melted mixture is shaped in films by the dies 
Advantage: 
 Fewer operation units 
 Better content uniformity 
 An anhydrous process 
3. Semi solid casting 
              Solution of water soluble film forming polymer is prepared 
 
           Resulting solution is added to a solution of acid insoluble polymer 
 
Appropriate amount of plasticizer is added to that gel mass is obtained 
 
Finally the gel is casted in to the films or ribbons using  
heat controlled drums 
 
4.  Solid dispersion extrusion 
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                        Drug is dissolved in a suitable liquid solvent            
 
The solution is incorporated in to melt of Polyethylene glycol  
obtained below 70°c 
 
Finally the solid dispersions are shaped in to the films by means of dies 
 
5. Rolling method 
Prepare pre-mix with film forming polymer, polar solvent 
And other additives except a drug 
 
Add premix to master batch feed tank 
 
Fed it via a first metering pumps and control valve to 
Either or both of the 1 st and 2nd mixer 
 
Add required amount of drug to the desired mixer 
 
Blend the drug with master batch premix to give a uniform matrix 
 
Specific amount of uniform matrix is then fed to the pan 
through 2nd metering pumps 
 
The film is finally forced on the substrate and carried  
away via the support roller 
 
The wet film is then dried using controlled bottom drying 
FORMULATION CONSIDERATION: (Aggarwal et al.,2011) 
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The area of drug loaded FDF should be between 1-20 cm2. The drug can 
be loaded up to a single dose of 30mg.All excipient used in the fast dissolving 
film should be generally regarded as safe (GRAS-listed) and authorized for use in 
oral strip. Formulation considerations have been reported as important factors 
which affected mechanical properties of the films. 
INGREDIENT AMOUNT 
1.  Drug(API) 5-30% 
2.  Water soluble polymer 45% 
3.  Plasticizer 0-20% 
4.  Saliva stimulating agent 2-6% 
5.  Surfactant Q.S. 
6.  Sweetening agent 3-6% 
7.  Flavours, colours, fillers Q.S. 
Formulations of FDOFs having the characteristics such as taste masking, 
fast dissolution, physical appearance, mouth feel etc. All excipients used in the 
formulation of FDOF should be Generally Regarded as Safe (i.e. GRAS-listed) 
and should be approved for use in oral pharmaceutical dosage forms.  
1. Drug Category 
 This technology has the potential for delivery of variety of APIs. However, 
there are some limitations like the size of the dosage form, drugs having high dose 
are difficult to be incorporated in films. Several classes of drugs can be formulated 
as fast dissolving films including antiulcer, antiasthamatics, antitussives, 
expectorants, antihistaminic and NSAID’S etc. 
2. Film Forming Polymers 
Water-soluble polymers are used as film formers as they provide rapid 
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disintegration, good Mouth feel and mechanical strength to the films. The 
robustness of the strip depends on the type of polymer and its amount in the 
formulations. Water-soluble polymeric film adheres to the bucosal mucosa and 
rapidly delivers medication into the systemic circulation. Various polymers are 
available for preparation of films of which pullulan, gelatin and hypromellose are 
most commonly used. Generally, 45%w/w of polymer should be present in the 
total weight of dry film. 
Table 1: Film forming polymers 
 
 
 
 
 
 
 
Ideal property of Film Forming Polymers:  
 It should be non toxic and non irritant 
 Polymer must be hydrophilic 
 It should have excellent film forming capacity 
 It should have good wetting and spread ability property 
 Polymer should be readily available & should not be very  expensive. 
 Polymer should have low molecular weight. 
 It should have sufficient shelf-life. 
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 Polymer must be tasteless, colorless. 
 It should not cause any secondary infection in oral mucosa. 
 It should exhibit adequate peel, shear and tensile strengths. 
3.  Plasticizers 
 It is a essential ingredient of the oral films. The selection of plasticizer 
depends upon its compatibility with the polymer and also the type of solvent 
employed in the casting of film. It improves the flexibility of the film and reduces 
the brittleness of the film. The strip properties of plasticizer are significantly 
improved by reducing the glass transition temperature of the polymer. They are 
used in the concentration of 1 - 20%w/w of dry polymer weight. Examples 
include: Glycerol, propylene glycol, Low molecular weight polyethylene glycols, 
Citrate derivatives like triacetin, acetyl citrate, phthalate derivatives like dimethyl, 
diethyl,dibutyl derivatives, Castor oil etc. 
4.  Sweetening agents 
 Sweeteners are the important part of the food products as well as 
pharmaceutical products. Incase of oral dosage form the sweet taste in formulation 
is more important especially for pediatric population. So, to improve the 
palatability of the mouth dissolving formulations natural sweeteners as well as 
artificial sweeteners are used. Following are the sweeteners which are suitable in 
FDF formulation: 
(a)  Water soluble natural sweetener: xylose, ribose, glucose, sucrose, maltose, 
stevioside etc. 
(b)  Water soluble artificial sweetener: sodium or calcium saccharin salts, 
cyclamate salts,acesulfame-k etc. 
(c)  Dipeptide based sweetener: aspartame 
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5.  Saliva stimulating agent (Kaur Mandeep et al.,2013) 
 The saliva stimulating agents are used to increase the rate of production of 
saliva that is helpful in the faster dissolution of the film formulations. Generally 
acids which are used in the preparation of food can be utilized as salivary 
stimulants. Examples of salivary stimulants are as follows: citric acid, malic acid, 
lactic acid, ascorbic acid and tartaric acid etc. Among these citric acid is most 
preferred saliva stimulating agent in the formulation. 
6. Flavoring agents (Gavaskar Basani et al.,2010) 
        Preferably up to 10%w/w flavors are added in the OFDF formulations The 
acceptance of the oral disintegrating or dissolving formulation by an individual is 
largely depends on the initial flavor quality which is observed in first few seconds 
after the product has been consumed and the after taste of the formulation which 
lasts for at least about 10 min. The selection of flavor is dependent on the type of 
drug to be incorporated in the formulation. It was observed that age plays a 
significant role in the taste fondness. The geriatric population like mint or orange 
flavors while younger generation like flavors like fruit punch, raspberry etc. 
Flavoring agents can be selected from synthetic flavor oils, oleo resins, extract 
derived from various parts of the plants like leaves, fruits and flowers. Flavors can 
be used alone or in the combination. Peppermint oil, cinnamon oil, spearmint oil, 
oil of nutmeg are examples of flavor oils while vanilla, cocoa, coffee, chocolate 
and citrus are fruity flavors. Apple, raspberry, cherry, pineapple are few examples 
of fruit essence type.  
 
7.  Colouring agents 
Titanium dioxide or FD&C approved colouring agents are incorporated 
(not exceeding concentration levels of 1%w/w) in FDF formulation when some of 
the formulation ingredients or drugs are present in insoluble or suspension form. 
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EVALUATION OF FILM 
1.  Weigh variation of Films 
 Mouths dissolving oral films were weighed on analytical balance and 
average weight can be determined for each film. It is desirable that films should 
have nearly constant weight. It is useful to ensure that a film contains the proper 
amount of excipients and API. 
2.  Thickness of Films 
 By using micrometer screw gauge the thickness of the film was measured 
at five different places; an average of three values was calculated. This is essential 
to ascertain uniformity in the thickness of the film this is directly related to the 
accuracy of dose in the film. 
3. Folding Endurance 
Folding endurance is measured by manual repeated folding of film at same 
place till it broke. 
The number of time the film is folded without breaking is known as the 
folding endurance value. (Sumitha C.H et al.,2009) 
4.  Tensile strength 
 Tensile strength is a maximum stress applied to a point at which the strip 
specimen breaks. It is calculated by applied load at rupture divided by the cross 
sectional area of the strip as  given in the following equation:  
Tensile strength =  Load at failure × 100/film thickness × film width 
5.  Percent Elongation 
 When stress is applied to a film sample it stretches and this is referred as 
strain. Strain is basically the deformation of film divided by original dimension of 
the sample. Generally elongation of film increases as the plasticizer content 
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increases.  
% Elongation = Increase in length× 100/ Initial length of film 
6.  Drug content uniformity 
 This is determined by any standard assay method described for the 
particular API in any of the standard pharmacopoeia. Content uniformity is 
determined by estimating the API content in individual strip. Limit of content 
uniformity is 85-115%. 
7.  Surface pH 
 The film to be tested was placed in a Petri dish and was moistened with 0.5 
ml of distilled water and kept for 30 s. The pH was noted after bringing the 
electrode of the pH meter in contact with the surface of the formulation and 
allowing equilibration for 1 min. The average of three determinations for each 
formulation was done. (Nagaret al.,2001) 
8. In vitro disintegration test 
 Disintegration time is the time when an oral film starts breaking when 
brought in contact with water or saliva. For a fast dissolving film, the time of 
disintegration should be in range of 5-30s. United State Pharmacopoeia (USP) 
disintegration apparatus can be used to study Disintegration time. In another 
method, the disintegration time can be visually determined by dipping the film in 
25 ml water in a beaker. The beaker should be shaken gently and the time was 
noted when the film starts to breaks or disintegrates. (Vishwkarma et al.,2001) 
9.  Dissolution test 
Dissolution testing can be performed using the standard basket or paddle 
apparatus described in any of the pharmacopoeia. The dissolution medium will 
essentially be selected as per the sink conditions and highest dose of the API. 
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Many times the dissolution test can be difficult due to tendency of the  
strip to float onto the dissolution medium when the paddle apparatus is employed. 
(Dixit RP et al., 2009) 
10.  Stability Testing 
Stability measurement is done by storing the of oral strip were stored 
under controlled conditions of 25ºC/60% RH as well as 40°C/75% over a period 
of 12 months in stability chamber according to the ICH guideline. During storage 
period various evaluating parameter like thickness, morphological properties, 
tensile strength, water content and dissolution behavior are checked. 
   Literature Review 
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LITERATURE REVIEW 
 
 Sandeep Saini et al.,(2011) formulated Fast dissolving film of 
levocetrizine dihydrochloride were prepared by solvent casting method by using 
Maltodextrin & HPMC E15 as the main film forming polymers. To decrease the 
disintegration time, concentration of maltodextrin & HPMC E15 were optimized 
be using 22 factorial design. Disintegration time, drug release pattern, mouth 
dissolving time and content uniformity were also evaluated. Compatibility 
between drug and recipients were studied by means of DSC analysis. Batch F1 
was found to be the optimized batch as its disintegration was completed within the 
minimum time as compared to all other batches. The formulation (F1) was also 
showing sufficient drug release after 5 min. All the 6 formulation was showing 
approximately 90% drug release after 5min. 
 
 Mital s panchal et al., (2012)Fast dissolving films of Ropinirole 
Hydrochloride were prepared by using  polymers such as pullulan and PEG 400 as 
plasticizer, by a solvent casting method. The formulated mouth dissolving films 
were evaluated for physical characteristics such as uniformity of weight, 
thickness, folding endurance, drug content uniformity, surface pH, percentage 
elongation, and tensile strength, and gave satisfactory results. The formulations 
were subjected to disintegration, In-vitro drug release tests and stability study. The 
FTIR and DSC studies revealed that no physicochemical interaction between 
excipients and drug. A marked increase in the % drug release was exhibited by 
mouth dissolving films of Ropinirole Hydrochloride containing pullulan as a 
polymer at 60 sec., when compared to other polymers films. Mouth dissolving 
film of Ropinirole Hydrochloride containing pullulan as polymer showed  
99.48 ± 0.18 % drug release at 60 sec.  
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 Mano Nagar et al.,(2012) formulated and evaluated  matrix type mouth 
dissolving films of Aripiprazole, prepared by solvent evaporation technique using 
Hydroxy propyl Methyl Cellulose (HPMC) - 3 cps. The formulated films were 
evaluated for their physiochemical parameters like mouth dissolving time, surface 
pH, thickness & weight of the films, PMA, PML, folding endurance, taste, drug 
content, stability and in vitro bioequivalence. In vitro release studies were also 
performed in solutions of different pH. The mouth dissolving film was found to be 
bioequivalent to the conventional solid dosage form of Aripiprazole. 
 
 
 Komagiri Sasi Deepthi et al., (2012) formulated atenolol fast dissolving 
films were formulated using film forming polymer like Hydroxy propyl 
methylcellulose (HPMC E5)(F1 – F8) and tween 80 is added to the formulation 
from F5 – F8 by solvent casting technique with the help of Polyethylene glycol 
(PEG 400) as a plasticizer and glycerine as a sweetening agent. FT-IR analysis 
was performed to study the interaction between the drug and polymer .The films 
were evaluated for weight variation, surface pH, folding endurance, drug content, 
dissolving time, disintegration time, in-vitro dissolution studies. Based on the 
evaluation parameters F4 containing Drug: Polymer (1:4) ratio showed optimum 
performance and marked increase in releasing of drug 92.34%, though F8 
formulation has maximum drug release as it has less tensile strength. It can be 
concluded in the study that mouth dissolving film can be potential novel drug 
dosage form for poorly water soluble drugs. 
 
 Buchi N Nalluri et al., (2013) formulating mouth dissolving films (MDFs) 
of the anti-asthmatic drug, Salbutamol Sulfate (SAL) to enhance convenience and 
compliance to the elderly and pediatric patients for better therapeutic efficacy. 
Film former, Hydroxy propyl Methylcellulose (HPMC) of different viscosity 
grades along with film modifier/solubilizing agents, polyvinyl pyrrolidone K30 
(PVP K30) and sodium lauryl sulphate (SLS) were used to formulate MDFs. The 
MDFs were prepared by wet film applicator technique and were evaluated for  
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in vitro dissolution characteristics, in vitro disintegration time, and their physico-
mechanical properties. MDFs with 13% (w/w) of HPMC E5 gave better 
dissolution properties when compared to HPMC E15.MDFs with 0.04% (w/w) of 
SLS gave superior dissolution properties when compared to MDFs without SLS. 
MDFs with 0.04% (w/w) PVP did not peel off from glass plate and hence were 
excluded from study.  
 
 Sumedha Bansal et al., (2013) formulated a fast dissolving film of 
Losartan potassium films of were prepared by solvent casting method using 
polymers such as PVA and Maltodextrin in different ratios. Propylene glycol was 
used as a plasticizer. Films were subjected to physicochemical characterization 
such as thickness, weight uniformity, folding endurance, drug content, surface pH 
study, in vitro drug release, ex vivo permeation study and stability studies. The  
in vitro drug release in optimized formulation F8 was found to be 78.62 % in 4 
min. The optimized formulation F8 also showed satisfactory pH, drug content 
(97.12%),), ex vivo permeation (89.42%), effective in vitro drug release (98.99% 
in 10min), disintegration time of 24 seconds and satisfactory stability. 
 
 
 Buchi N. Nalluri et al.,(2013)  formulating mouth dissolving films (MDFs)  
Sumatriptan Succinate (SUM) Film former, Hydroxy Propyl Methyl Cellulose 
along with  film modifier/solubilizing agents, Polyvinyl pyrrolidone K30 (PVP 
K30) and Sodium Lauryl Sulphate (SLS) were used to formulate MDFs. The 
MDFs were prepared by wet film applicator technique and were evaluated for in-
vitro dissolution characteristics, in vitro disintegration time, and their physico-
mechanical properties. MDFs with 13% (w/w) of HPMC E5 gave better 
dissolution properties when compared to HPMC E15. MDFs with PVP K30and 
SLS gave superior dissolution properties when compared to MDFs without PVP 
K30 and SLS. The dissolution properties of MDFs with PVP K30 were superior 
when compared to MDFs with SLS.  
 H.D. Karen et al.,(2013) developed Loratadine mouth dissolving films 
using HPMC E15 LV PREMIUM as film forming polymer, glycerin as a 
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plasticizer and tween 80 as a surfactant. The strips were evaluated for thickness, 
tensile strength, % elongation, disintegration time and in vitro drug release. A trial 
and error approach was used in present study for optimization. Oral strip 
containing HPMC E15 LV PREMIUM (190mg), tween 80 (15% of polymer) and 
glycerin (20% of polymer) has given the maximum in vitro drug release and 
imparts good transparency. A satisfactory result in the strip was exhibited in the 
way of in vitro release that came in 20 minutes. The drug excipients compatibility 
study showed that there were no interaction between drug and excipients. Stability 
study of the optimized formulation showed that the strips were stable at 
accelerated environmental conditions.  
 
 K.M.Mageshwari et al..,(2014) formulated mouth dissolving films (MDFs) 
of Amlodipine Besylate(AMLO) using Film formers like hydroxy propyl methyl 
cellulose (HPMC) and methyl cellulose (MC) along with film modifiers like poly 
vinyl pyrrolidone K30(PVP K30), and sodium lauryl sulphate (SLS) as 
solubilizing agents were evaluated. The prepared MDFs were evaluated for  
in vitro dissolution characteristics, in vitro disintegration time, and their physico 
mechanical properties. All the prepared MDFs showed good mechanical 
properties like tensile strength, folding endurance, and % elongation. MDFs were 
evaluated by means of FTIR, SEM, and X-RD studies. MDFs with 7.5% (w/w) of 
HPMC E3 gave better dissolution properties when compared to HPMC E5, 
HPMC E15, and MC. Release kinetics data reveals diffusion is the release 
mechanism. 
 
 Ravi Kumar K and Mercy Sulochana M (2014)formulated  Lercanidipine 
hydrochloride fast dissolving films using polymers like HPMC E15, PVA as 
polymers and sodium starch glycolate, crospovidone as superdisintegrants by 
solvent casting method. Formulation HF2 with HPMC E15 and crospovidone is 
considered as the optimized formulation as it showed faster disintegration rate 
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(28sec), maximum in vitro drug release i.e., 98.84% within 10mins. No significant 
changes were observed during stability studies for the optimized formulation. It 
was concluded that Lercanidipine hydrochloride fast dissolving oral films can be 
formulated as a potentially useful tool for an effective treatment of hypertension 
and management of angina pectoris with improved bioavailability, rapid onset of 
action and with increased patient compliance. 
 
 Vidhi Desai, Nihar Shah (2014) formulated mouth dissolving films of 
Olmesartan Medoxomil, prepared by solvent casting technique. Film made up of 
different polymers but combination of HPMC E15 and PVA was optimized as 
final formulation. The prepared films were evaluated for organoleptic evaluations, 
film weight, thickness, folding endurance, tensile strength, drug content 
uniformity of films, surface PH disintegration time and in-vitro dissolution 
studies. 
 
 Kamalesh upreti et al., (2014) formulated mouth dissolving films of 
paracetamol were prepared by solvent casting method, using polymer like 
(hydroxy propyl methyl cellulose) and plasticizer (glycerol) concentrations. 
Sweetening and flavoring agents were also added to make the formulation 
palatable. The films were evaluated for thickness, folding endurance, weight 
variation, disintegration time, dissolution time and drug content. Thickness of the 
films was approximately 2 mm. The strips disintegrated completely within 4 
minutes. In-vitro dissolution studies were carried out in distilled water as well as 
in simulated salivary fluid (pH 6.8).The optimized formulation showed 92% drug 
release within 30 min. The prepared strips seem to be an attractive alternative to 
conventional marketed formulations. 
 
 
 Ambikar R B et al.,(2014) Formulated herbal oral dissolving films contain 
herbal plants extract and powders of Ocimum tenuiflorum (tulasi), Azadiracta 
indica (neem), Syzygium aromaticum (lavanga),Boerhaavia diffusa (punarnava), 
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Glycyrrhiza glabra (yastimadhu), Jasminum grandiflorum (jasmine),(triphala). 
These plants possess antiulcer, astringent, antimicrobial and anti-inflammatory 
activity. HPMC and ethyl cellulose for the formulation of the films suitable 
polymers and plasticizers are selected. The films were subjected to physical 
investigations such as uniformity of thickness, weight, drug content, folding 
endurance, tensile strength, surface pH. Also evaluation of the films is done by 
using parameter like disintegration time, % moisture absorption, % moisture loss, 
surface pH, swelling index etc. The obtained results for prepared herbal films 
indicate that was higher for those formulations containing higher percentage of 
HPMC. 
 
 Pandya Ketul et al.,(2014) formulated fast dissolving film of Telmisartan 
was prepared using Pullulan as film forming polymer. To decreases the 
disintegration time microcrystalline cellulose was used as filler. All the films were 
evaluated for their Thickness, Folding endurance, Tensile strength, % elongation, 
Disintegration time, In vitro drug release, and Stability study. The formulation F9 
shows higher drug content (93.9%), Less Disintegration Time (33sec), Tensile 
Strength and Folding endurance respectively 0.249 N/mm2 and 243. Film of batch 
F9 was disintegrated with 33 second, Releases 93.22% drug within 16 minutes 
during the in vitro dissolution test and there was no significant change is shown 
during stability study. 
 
 Poonam A Padamwar et al.,(2015) formulated Bisoprolol Fumarate film 
were prepared by using polymers such as hydroxy propyl methyl cellulose 
(HPMC) and Maltodextrin, plasticizer such as PEG 400, by a solvent casting 
method. They were evaluated for physical characteristics such as thickness, 
uniformity of weight, folding endurance, drug content, surface ph, percentage 
elongation and tensile strength and give satisfactory results. The formulations 
were subjected to disintegration, in-vitro drug release test. The in vitro 
disintegration time of the optimized batch F4 was found to be 20 sec. The 
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optimized batch was found to be stable for 1 month underspecified stability 
conditions. 
 
 D Nagendra Kumar et al., (2015) formulated metaprolol succinate fast 
dissolving films using polymers like HPMC E5 and HEC polymer by solvent 
casting method. The prepared films were evaluated for organoleptic evaluations, 
film weight, thickness, folding endurance, tensile strength, drug content 
uniformity of films, surface PH disintegration time and in vitro dissolution 
studies. the formulation F5 has disintegration time of 7 seconds and is more 
promising and showed drug release of 98% after 5 minutes; hence formulation  
F5 was selected as best formulation. 
 
 P Bhatt M Patel (2015) formulated Rizatriptan benzoate mouth dissolving 
films using polymers like HPMC, PVA, PVP K30, Xanthan gum, Guar gum. 
Citric acid was used as a saliva stimulating agent and Propylene glycol as a 
plasticizer. The prepared oral films were evaluated for their physicochemical and 
mechanical parameters such as Physical appearance, surface pH, thickness 
uniformity, disintegration time, drug content uniformity, folding endurance, 
tensile strength, percentage elongation, in-vitro drug release. The polymer 
combination of HPMC E 15 & PVA was optimized. On applying factorial design 
to this combination, batch with polymer ratio of 1:7 (HPMC: PVA) was 
optimized. The formulation was found stable after 1 month. 
 
 Vasavi Geedi et al.,(2015) formulated Fast Dissolving Oral Films of 
Zolmitriptan Films were prepared by solvent casting method using Natural 
Polymers Xanthan gum, Guar Gum, Sodium Alginate, Aloe vera Powder as the 
film forming polymer and PEG-400 as the plasticizer. Vanillin was used as taste 
masking agent in the formulation. The thickness, folding Endurance, 
disintegration time, % drug released and drug content were selected as dependent 
variables. The optimized formulation, F6 was found superior than remaining 7 
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batches. Among all the formulations, F6 has shown maximum drug release of 
99.1±0.05% within 8 min and a very low disintegration time of 8.33±0.57sec due 
to super-disintegrant Sodium Starch Glycolate. Hence the films made of 2%w/v of 
Sodium Alginate and PEG-400 showed excellent film forming property with rapid 
drug release profile. FT-IR studies revealed that there was no physico-chemical 
interaction between polymer and drug. Stability studies revealed that optimized 
formulation was stable as the % drug release at the end of 3rd month was 99.1%.  
 
 Smita V. Pawar, M. S. Junagade (2015) formulated Risperidone fast 
dissolving films were formulated by solvent-casting method containing HPMC E5 
as polymer and Propylene glycol as plasticizer. All films prepared were smooth 
and elegant in appearance and showed no visible cracks; were uniform in 
thickness, weight and drug content. Formulation A2 is considered as the 
optimized formulation as it showed good % elongation (120%), good folding 
endurance (185), faster disintegration rate (13 sec.) and maximum in vitro drug 
release (93.57%) within 10 mins. No significant changes were observed during 
stability studies for the optimized formulation. It was concluded that Risperidone 
fast dissolving oral films can be formulated as a potentially useful tool for an 
effective treatment of Schizophrenia with improved bioavailability, rapid onset of 
action and with increased patient compliance. 
 
 Safila Naveed et al.,(2015) analyzed method development of perindopril. It 
is an angiotensin-converting-enzyme inhibitor (ACE inhibitor). In this method 
measurement of absorbance at the wavelength of maximum absorptions of 
Perindopril using water as a solvent is done. The calibration curve was linear in 
concentration range of 12.5-200 μg/ml for Perindopril with correlation coefficient 
of 0.9991. The accuracy and precision of the method was determined and 
validated statically. The method showed good recovery with % RSD less than 2 
and good reproducibility. Method was found to be rapid, specific, precise and 
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accurate. This method can be successfully applied for the routine analysis of 
perindopril Accuracy of proposed method was confirmed by performing accuracy 
studies which showed the accepted results. Precision of proposed method was 
confirmed by performing intraday and inter day precision. The method for the 
determination of perindopril was validated according to ICH guidelines. 
 
 Anjum Pathan et al., (2016) formulated and evaluate the Fast dissolving 
Oral film of Promethazine hydrochloride. The films were prepared Hydroxy 
propyl methyl cellulose E15 as a film base synthetic polymer and PEG400 (Poly 
Ethylene Glycol 400) as a plasticizer by solvent casting method. SLS (Sodium 
Lauryl Sulfate) and MCC (Micro Crystalline Cellulose) used as a surfactant in 
different concentration. Sucrose used as a sweetening agent and strawberry as a 
flavoring agent. Films were found to be satisfactory when evaluated for thickness, 
weight uniformity, in-vitro drug release, folding endurance, drug content and 
disintegration time. The in vitro drug release in optimized formulation F2 was 
found to be 14.36% in 2 min. The optimized formulation F2 also showed 
satisfactory pH, drug content (97.41±0.54%), effective in vitro drug release 
(96.03±0.68% in 16 min), disintegration time of 09 seconds and satisfactory 
stability. 
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POLYMER PROFILE 
XANTHAN GUM 
Synonyms 
 Corn sugar gum; E415; Keltrol; merezan; polysaccharide B-1459; xanthan 
gum. 
 
Functional category 
 Stabilizing agent; suspending agent; viscosity-increasing agent. 
Typical properties 
Acidity/alkalinity pH : 6-8 for a 1% w/v aqueous solution 
Melting point                           :     270 °C 
Heat of combustion                 : 14.6 J g 
Specific gravity     :  1.600 at 25°C 
Viscosity :  1200-1600mPa. 
Solubility 
 Practically insoluble in ethanol and ether. Soluble cold or warm water. 
Description 
Xanthan gum occurs as a cream or white –colored, odorless, free-flowing, 
fine powder. 
Stability and storage conditions 
Xanthan gum is a stable material. Aqueous solutions are over a wide pH 
range (pH 3-12) and temperatures between 60°C. Xanthan gum solutions less 
than1% w/v concentration may be adversely affected by higher than ambient 
temperatures. 
Application in pharmaceutical formulation or technology 
 Polymer Profile 
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 Xanthan gum is widely used in oral and topical pharmaceutical 
formulations, cosmetics and food as a suspending and stabilizing agent. It is non-
toxic, compatible with most other pharmaceutical ingredients and has good 
stability and viscosity properties over a wide pH and temperature range. Although 
primarily used as a suspending agent Xanthan gum has also been used to prepare 
sustained release matrix tablets. Similarly optimum synergistic effects are 
obtained with Xanthan gum. 
Safety 
 Xanthan gum is widely used in oral and topical pharmaceutical 
formulations, cosmetics and food products and is generally regarded as nontoxic 
and nonirritant at the levels employed as a pharmaceutical excipient.  
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SODIUM ALGINATE 
Synonyms  
 Algin; alginic acid; sodium salt; E401; kelcosol; keltone; manucol; 
manugel; pronova; satialgine-H8. 
Molecular weight 
 1828 
Functional category 
 Stabilizing agent ; suspending agent; tablet and capsule disintegrant; tablet 
binder; viscosity-increasing agent. 
Typical properties 
 pH : 7.2(for a 1% w/v aqueous solution) 
 Melting point :  20oC. 
 Specific gravity  :  1.26. 
 Viscosity             :     20-400 mPa 
Solubility 
 Practically insoluble in ethanol and ether. Also insoluble in other organic 
solvents and acid. Slowly soluble in water, forminga viscous colloidal solution. 
Description 
 Sodium alginate occurs as an odorless and tasteless, white to pale 
yellowish-brown colored powder. 
Applications in Pharmaceutical formulation or Technology 
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 Sodiumalginate is used in a variety of oral and topical pharmaceutical 
formulations. In tablet formulation sodium alginate may be used as a both binder 
and disintegrant. It has also been used for preparation of sustained release oral 
formulations since it can delay the dissolution of a drug from tablets. In topical 
formulations sodium alginate is widely used as a thickening and suspending agent 
in variety of creams and gels and as a stabilizing agent for oil in water emulsion. 
Safety 
Sodium alginate is widely used in cosmetics, food products and 
pharmaceutical formulations. It is generally regarded as a non-toxic and non 
irritant material although excessive oral consumption may be harmful. 
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PECTIN 
Synonyms 
 Cellulose, kaopectate 
Functional category 
 Stabilizing agent; gelling agent; thickening agent 
Typical properties 
Acidity/alkalinity pH : 3.2-4.5 
Melting point                            :     270 °C 
Heat of combustion                   : 14.6 J g 
Specific gravity     :  1.600 at 25°C 
Viscosity :  1200-1600 mPa. 
Solubility 
  Pectin is soluble in pure water, partially soluble in cold water. It is 
Insoluble in organic solvents and alcohol. 
Description 
Pectin occurs as a white, amorphous, odorless, free-flowing, fine powder. 
Stability and storage conditions 
 Pectin  is a stable material. Aqueous solutions are over a wide pH range 
(pH 3-12) and temperatures between 60°C. Xanthan gum solutions less than1% 
w/v concentration may be adversely affected by higher than ambient temperatures.   
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Application in pharmaceutical formulation or technology 
 Pectin is widely used in oral and topical pharmaceutical formulations, 
gelling agent, thickener, water binder and stabilizer. It is non-toxic, compatible 
with most other pharmaceutical ingredients and has good stability and viscosity 
properties over a wide pH and temperature range.  
Safety 
 Pectin is widely used in oral and topical pharmaceutical formulations, 
cosmetics and food products and is generally regarded as nontoxic and nonirritant 
at the levels employed as a pharmaceutical excipient.  
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DRUG PROFILE 
 
Synonyms  :        Perindopril 
IUPAC Name : (2S,3AS.7as)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-
2-yl]amino}propanoyl]octahydro-1H-indole-2-
carboxylic perindoprilium. 
Empirical Formula : C19H32N2O5.C4H11N 
 
Structural Formula: 
 
Molecular Weight  :  368.468g/mol  
Description  : White to off white powder. 
Solubility  : Water, Methanol, Chloroform. 
Melting point : 100-101° C. 
Partition coefficient   : Log P (n-octanol / water) is 3.018. 
Storage  : Store perindopril at room temperature, between 68-
77° F. Store away from heat, light and moisture. 
Category : ACE Inhibitor 
Action and use : Perindopril is used in the treatment of hypertension 
and heart failure 
 
. 
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Mode of action: 
There are two isoforms of ACE: the somatic isoform, which exists as a 
glycoprotein comprised of a single polypeptide chain of 1277; and the testicular 
isoform, which has a lower molecular mass and is thought to play a role in sperm 
maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two 
functionally active domains, N and C, which arise from tandem gene duplication. 
Although the two domains have high sequence similarity, they play distinct 
physiological roles. The C-domain is predominantly involved in blood pressure 
regulation while the N-domain plays a role in hematopoietic stem cell 
differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of 
both domains, but have much greater affinity for and inhibitory activity against 
the C-domain. 
Perindoprilat, the active metabolite of perindopril, competes with ATI for 
binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. 
Decreasing ATII levels in the body decreases blood pressure by inhibiting the 
pressor effects of ATII as described in the Pharmacology section above. 
Perindopril also causes an increase in plasma renin activity likely due to a loss of 
feedback inhibition mediated by ATII on the release of renin and/or stimulation of 
reflex mechanisms via baro receptors. 
 
Pharmacokinetics: 
Absorption and bioavailability: 
Rapidly absorbed with peak plasma concentrations occurring 
approximately 1 hour after oral administration. Bioavailability is 65-75%. 
Following absorption, perindopril is hydrolyzed to Perindoprilat, which has an 
average bioavailability of 20%.  
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 The rate and extent of absorption is unaffected by food. However, food 
decreases the extent of biotransformation to Perindoprilat and reduces its 
bioavailability by 35%. 
Distribution: 
Approximately 60% of circulating Perindopril is bound to plasma proteins, 
and only 10 to 20% of Perindoprilat is bound. Therefore, drug interactions 
mediated through effects on protein binding are not anticipated. 
 
Biotransformation: 
Extensively metabolized, with only 4-12% of the dose recovered in urine 
following oral administration. Six metabolites have been identified: Perindoprilat, 
perindopril glucuronide, Perindoprilat glucuronide, a perindopril lactams, and two 
Perindoprilat lactams. Only Perindoprilat is pharmacologically active. 
Perindoprilat and Perindoprilat glucuronide are the two main circulating 
metabolites. 
 
Elimination: 
Perindopril is extensively metabolized following oral administration, with 
only 4 to 12% of the dose recovered unchanged in the urine. 
Dose: 
Use in Uncomplicated Hypertensive Patients: 
In patients with essential hypertension, the recommended initial dose is  
4 mg once a day. The dose may be titrated, as needed to a maximum of 16 mg per 
day.  
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Use in Elderly Patients:  
The recommended initial daily dosage of Perindopril for the elderly is4 mg 
daily, given in one or two divided doses. 
Side Effects: 
Heart  
Slow heart rate, palpitations, heart block, abnormal heart rhythm, difficulty 
in breathing and chest pain. 
 
Central Nervous System 
Headache and dizziness. 
Eye  
Blurred vision. 
Gastrointestinal  
Nausea, vomiting and stomach pain. 
Musculoskeletal  
Muscle cramps and muscle weakness. 
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PLAN OF WORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preformulation studies 
Formulation of films 
Calibration of 
standard curve 
Solubility 
studies 
Preparation of mouth dissolving films  
using a different polymers 
 FT-IR compatibility 
 DSC study 
 
Characterization of Rims 
 SEM 
 Thickness 
 Folding endurance 
 Weight variation 
 Surface pH 
 Drug Content uniformity 
 Disintegration time 
t i ti  f fil  
In vitro Drug diffusion study 
In vitro drug release kinetics 
Stability study 
 Materials & Equipments 
 
 
 
 
Department of Pharmaceutics  37 
 
MATERIALS AND EQUIPMENTS 
MATERIALS USED 
          MATERIAL                     SOURCE 
Perindopril  Hetero Drugs Ltd, Hyderabad. 
Xanthan gum  Loba Chemicals,Mumbai. 
Sodium alginate Ozone International,Mumbai. 
Pectin  Himedia Laboratories, Mumbai. 
Sodium starch glycolate Loba chemical Pvt Ltd, Mumbai. 
Poly ethylene glycol  (400) Qualigens  Fine Chemicals,Mumbai. 
Vanillin  Himedia Laboratories, Mumbai. 
Sucrose  Sisco Research Laboratories, Mumbai. 
Pottasium dihydrogen phosphate Himedia Laboratories, Mumbai 
Disodium hydrogen phosphate Sd Fine Chemicals, Mumbai 
  
EQUIPMENTS USED 
          EQUIPMENT          MODEL/COMPANY 
DSC Shimadzu corporation, japan. 
Uv-visible spectrophotometer Jasco V 530 
FT-IR Spectrophotometer Jasco-FTIR 4100 
Digital  balance Shimadzu  corporation japan 
Dissolution  test apparatus Electro lab TDT 08L 
pH tester Eutech instruments 
Disintegration tester Campbell electronics, Bombay. 
SEM JSM 6390, Make – JEOL 
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EXPERIMENTAL METHODS 
 
ESTIMATION OF PERINDOPRIL 
 The methods for estimation of perindopril reported include Ultra Violet 
(PanchumarthyRavisankar et al., 2015), High Performance Liquid 
Chromatography (Nagaraju et al., 2014), Reverse Phase High Performance Liquid 
Chromatography (Krishna Chaitanya Prasad et al., 2013), High Performance Thin 
Layer Chromatography (Santosh et al., 2014). 
 
Method used for the estimation of perindopril in this present investigation 
 A uv spectrophotometric method based on the measurement of absorbance 
at 210 nm was used in the present study for the estimation of perindopril for the 
samples. Calibration curves were constructed for the perindopril in 20-100µg/ml. 
 
Construction of calibration curve of perindopril by UV spectrophotometry 
Preparation of pH 6.8 phosphate buffer (IP 2007 vol 1) 
 Dissolve 28.8g of disodium hydrogen phosphate and 11.45g of potassium 
dihydrogen phosphate in sufficient water to produce 1000 ml. 
 
Calibration graphs preparation in Phosphate buffer pH 6.8  
100 mg of pure drug perindopril was accurately weighed and transferred to 
100 ml of volumetric flask. Drug was dissolved in phosphate buffer 6.8 and 
volume was made up to 100 ml. The concentration of drug was 1000 µg/ml.  
 
Standard solution  
100mg of perindopril was dissolved in a 100 ml of volumetric flask and 
this solution was made up to the mark with water. 
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Procedure for plotting calibration curve of pure drug 
 From the standard solution of perindopril was subsequently diluted with 
water to obtain a series of dilutions containing 20-100 µg/ml of perindopril in 1 
ml solution. The absorbance of these solutions was measured at 221 nm UV 
spectrophotometer (JASCOV530) against corresponding blank. The concentration 
of perindopril and the corresponding absorbance values are given in table 5. The 
calibration curves for the estimation of perindopril were constructed by plotting 
linear best fit between concentration of perindopril and corresponding mean 
absorbance value are shown in figure 2. 
 
IDENTIFICATION OF PERINDOPRIL 
Perindopril was received as a gift sample from CTX Life Science Pvt. Ltd, 
India. 
 
Fourier Transform Infrared (FT-IR) Spectroscopy  
  FT-IR spectrum of drug was recorded using a JASCO 4100. The diffuse 
reflectance technique was utilized in the mid IR 4000-400 cm-1 spectral region. 
The procedure consist of dispersing the sample in kbr (100mg) using a motor, 
triturating the materials into a fine powder bed into the holder using compression 
gauge. The pressure was around 5 tons for 5 min. The pellet was placed light path 
and the spectrum was recorded in duplicate, the characteristic peaks of the 
functional groups were interpreted. 
 
UV Spectroscopy  
 An accurately weighed 10 mg of drug was dissolved in 10 ml water. From 
the primary stock solution 20 µg/ml of perindopril solution was prepared 
phosphate buffer solution. This solution was scanned between 200-400 nm. 
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PREPARATION OF PERINDOPRIL MOUTH DISSOLVING FILMS 
Solvent casting method involves firstly the water soluble polymers are 
dissolved in water at 1,000 rpm and can be heated up to 60°C. All the other 
excipients like colors, flavoring agent, sweetening agent, etc., are dissolved 
separately. Then both the solutions obtained are mixed thoroughly stirring at 
1,000 rpm. The obtained solution is incorporated with the API dissolved in 
suitable solvent. The entrapped air is removed by vacuum. The resulting solution 
is cast as a film and allowed to dry, which is then cut into pieces of the desired 
size. The formulation codes are given in the table4. 
 
Table 2: Composition of fast dissolving films of perindopril using Xanthan 
gum (F1-F5) 
INGREDIENTS FORMULATION 
Formulation code F1 F2 F3 F4 F5 
Drug (mg) 20 20 20 20 20 
Xanthan gum(mg) 100 150 200 250 300 
Poly ethylene glycol 400(ml) 0.4 0.4 0.4 0.4 0.4 
Sodium starch glycolate(mg) 10 10 10 10 10 
Citric acid (mg) 5 5 5 5 5 
Sucrose(mg) 5 5 5 5 5 
Vanillin(mg) 5 5 5 5 5 
Amaranth(mg) qs qs qs qs qs 
Water(ml) 8 8 8 8 8 
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Table 3: Composition of fast dissolving films of perindopril using  
sodium alginate (F6-F10) 
INGREDIENTS FORMULATION 
Formulation code F6 F7 F8 F9 F10 
Drug (mg) 20 20 20 20 20 
Sodium alginate (mg) 100 150 200 250 300 
Poly ethylene glycol 400(ml) 0.4 0.4 0.4 0.4 0.4 
Sodium starch glycolate(mg) 10 10 10 10 10 
Citric acid (mg) 5 5 5 5 5 
Sucrose(mg) 5 5 5 5 5 
Vanillin(mg) 5 5 5 5 5 
Amaranth(mg) qs qs qs qs qs 
Water(ml) 8 8 8 8 8 
 
Table 4: Composition of fast dissolving films of perindopril using  
pectin (F11-F15) 
INGREDIENTS FORMULATION 
Formulation code F11 F12 F13 F14 F15 
Drug (mg) 20 20 20 20 20 
Pectin (mg) 100 150 200 250 300 
poly ethylene glycol 400(ml) 0.4 0.4 0.4 0.4 0.4 
Sodium starch glycolate(mg) 10 10 10 10 10 
Citric acid (mg) 5 5 5 5 5 
Sucrose(mg) 5 5 5 5 5 
vanillin(mg) 5 5 5 5 5 
Amaranth(mg) qs qs qs qs qs 
Water(ml) 8 8 8 8 8 
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DRUG-EXCIPIENTCOMPATIBILITY STUDIES 
 Before formulation of a drug substance into a dosage form, it is essential 
that it should be chemically and physically compatibility. Compatibility studies 
give the information needed to define the nature of the drug substance and provide 
a frame work for the drug combination with pharmaceutical excipients in the 
fabrication of a dosage form. 
 One of the requirements for the selection of suitable excipients or carrier 
for pharmaceutical formulation is its compatibility. Therefore in the present work, 
a study was carried out by using infrared spectrophotometer to find out if there is 
any possible chemical interaction between perindopril and excipients. 
 Weighed 3 mg of drug was mixed with 100 mg of potassium bromide 
(dried at 40-50˚c). The mixture was taken and compressed under 10-ton pressure 
in hydraulic press to form a transparent pellet. The pellet was scanned from 4000-
400cm-1 in IR spectrophotometer. 
The result was shown in Figure 3-9. 
FT-IR peak matching 
FT-IR spectra matching approach of the FT-IR data was employed for 
detection of chemical interaction between the drug and selected polymers. The 
chemical interaction between drug and polymer can be identified by changes in 
the peak (characteristic wave numbers). Physical mixture of drug, polymer and 
drug & polymer were prepared and mixed with suitable quantity of potassium 
bromide separately. About 100 mg of this sample was compressed to form a 
transparent pellet using a hydraulic press at 15 tons pressure. It was scanned from 
4000-400/cm. FT-IR spectra of pure drug, polymer and drug formulation was 
compared to detect any appearance or disappearance of peaks. 
 
Drug-Excipient Compatibility Studies by DSC: 
Experimental Methods 
 
 
 
Department of Pharmaceutics 43 
 
DSC thermo grams of pure drug (perindopril) and its physical mixture 
with polymer (pectin) were carried out to investigate any possible interaction 
between the drug and the utilized polymer (Pectin).The selected heating rate is 
from 50°C to 300°C at an increase of 20°C per minute using Differential Scanning 
Calorimeter (Shimadzu corporation, Japan) 
 
CHARACTERIZATION OF FILMS 
Scanning electron microscope 
The surface morphology of optimized formulation was studied using 
scanning electron microscopy. A scanning electron microscopic sample holder 
with a double sided taps and coated with a layer of gold of 150˚A for 2 min using 
a sputter coater(JSM 6390, Make – JEOL) in a vaccum of 3×10-1atm of organ gas. 
The samples were then examined using a scanning electron microscope (Gupta 
Dilip Kumar et al., 2014). 
 
Weight variation 
           Mouths dissolving oral films were weighed on analytical balance and 
average weight can be determined for each film. It is desirable that films should 
have nearly constant weight. It is useful to ensure that a film contains the proper 
amount of excipients and API. 
 
Thickness of Films 
           By using micrometer screw gauge the thickness of the film was measured 
at five different places; an average of three values was calculated. This is essential 
to ascertain uniformity in the thickness of the film this is directly related to the 
accuracy of dose in the film. (Swapnali V Bande et al.,2007) 
 
Folding endurance  
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Folding endurance was determined by repeated folding of the strip at the 
same place till the strip breaks. The number of times the film was folded without 
breaking is computed as the folding endurance value. (Arya A., 2010) 
 
Drug content uniformity 
        This is determined by any standard assay method described for the particular 
API in any of the standard pharmacopoeia. Content uniformity is determined by 
estimating the API content in individual strip. Limit of content uniformity is 85-
115%. (Sharma R et al., 2005) 
 
Surface pH 
    The film to be tested was placed in a Petri dish and was moistened with 0.5 
ml of distilled water and kept for 30 s. The pH was noted after bringing the 
electrode of the pH meter in contact with the surface of the formulation and 
allowing equilibration for 1 min. The average of three determinations for each 
formulation was done. (Kumar GV et al.,2005) 
 
In vitro disintegration test 
 Disintegration time is the time when an oral film starts breaking when 
brought in contact with water or saliva. For a fast dissolving film, the time of 
disintegration should be in range of 5-30s. United State Pharmacopoeia (USP) 
disintegration apparatus was used to studydisintegration time. In another method, 
the disintegration time was visually determined by dipping the film in 25 ml water 
in a beaker. The beaker was shaken gently and the time was noted when the film 
starts to breaks or disintegrates. (Vishwkarma DK et al.,2011) 
 
In vitro diffusion studies 
In vitro drug release studies were performed by using Franz diffusion cell 
with dialysis membrane. It consists of a donor compartment and a receptor 
compartment. The receptor compartment was filled with 20ml of phosphate buffer 
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solution as a diffusion medium. The prepared film was taken in the receptor 
compartment the medium was continuously stirred at 50 rpm using magnetic 
beads and the temperature was maintained at 37±1˚C. 1ml sample of receptor 
fluid was withdrawn at predetermined intervals and volume was replaced with 
same volume of 1ml phosphate buffer solution. The sample was analyzed 
spectrophotometrically at 210 nm using JASCO V 530uv spectrophotometer. The 
cumulative amount of drug permitted was calculated and plotted against time. 
(Rahul Nair et al.,2012). 
 
In vitro drug release kinetics 
The order and mechanism of drug release kinetics of perindopril films was 
analyzed by the invitro diffusion study data by plotting the following kinetic 
models, (zero order, first order and Higuchi equations and  release was determined 
by using Korsmeyer-Peppas equations. 
 
Zero-Order Kinetics: 
Cumulative amount of drug released was plotted against time.  
 C = K0t 
 
WhereK0 is the zero-order rate constant expressed in units of 
concentration/time and t is the time in hours. A graph of concentration Vs time 
would yield a straight line with a slope equal to K0 and intercept the origin of the 
axis. This kinetics describes concentration independent drug release from the 
formulations. 
 
First order kinetics:  
First order as log cumulative percentage of drug remaining vs time. This 
kinetics describes concentration dependent drug release from the formulations.   
Log C = Log Co-kt / 2.303 
WhereC0 is the initial concentration of drug, k is the first order constant, 
and t is the time. 
Higuchi’s Model:  
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Higuchi’s model as cumulative percentage of drug released vs square root 
of time.  
Q = Kt1/2 
 Where K is the constant reflecting the design variables of the system and t 
is the time in hours. This model describes the release of drug on the basis of 
Fickian diffusion as a square root of time dependent process from swellable 
matrix. 
Korsemeyer-Peppas Equations:  
The mechanism of drug release, the first 60% of drug release were plotted 
in Korsemeyer et al’s equation log cumulative percentage of drug released vs log 
time, and the exponent n was calculated through the slope of the straight line,  
Mt / M∞ = Ktn 
Where Mt/M∞ is the fractional solute release, t is the release time,  
K is a kinetic constant. Characteristic of the drug/polymer system, and n is an 
exponent that characterizes the mechanism of release of tracers. For cylindrical 
matrix tablets, if the exponent n = 0.45, then the drug release mechanism is 
Fickian diffusion, and if 0.45 <n < 0.89, then it is non-Fickian or anomalous 
diffusion. An exponent value of 0.89 is indicative of Case-II Transport or typical 
zero-order release (Balaiah et al.,2012). 
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RESULTS AND DISCUSSION 
 
ANALYTICAL METHOD TO DETERMINE PERINDOPRIL 
Estimation of perindopril using UV Spectrophotometry  
Perindopril was estimated using UV spectrophotometry measured at  
210 nm using phosphate buffer (pH 6.8). 
Table 5: Estimation of perindopril measured at 210 nm in phosphate buffer 
(pH 6.8) using uv spectrophotometry 
S.No Concentration (μg/ml) Absorbance at 210nm 
1 20 0.2045±0.0045 
2 40 0.4021±0.0021 
3 60 0.6125±0.0025 
4 80 0.7923±0.052 
5 100 1.0100±0.083 
 
 
Figure 2: Estimation of perindopril measured at 210 nm in phosphate buffer 
(pH 6.8) using UV spectrophotometry 
Conc (g/ml) 
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It was observed that the concentration range of 2-10μg /ml obeyed the 
Beer’s Lambert’s law. The correlation coefficient was found to be  
R = 0.998816.  
COMPATIBILITY STUDIES 
           The compatibility study between drug and the carriers was carried out 
using FTIR spectrometer. The peak numbers of the drug exhibiting  
O-H, C-H, C-C, C=N stretching were observed and are depicted as below.  
(Skoog DA et al., 2007) 
 
Figure 3: FTIR spectrum of perindopril 
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Figure 4: FTIR spectrum of Xanthan gum 
 
 
 
Figure 5: FTIR spectrum of Pectin 
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Figure 6: FTIR spectrum of sodium alginate 
 
 
Figure 7: FTIR spectrum of perindopril with Xanthan gum 
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Figure 7: FTIR spectrum of perindopril with pectin 
 
 
Figure 9: FTIR spectrum of perindopril with sodium alginate 
Table 6: IR spectrum of perindopril and excipients  
(sodium alginate, guar gum, pectin)(Skoog DA et al., 2007) 
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Functional group 
assignment 
Standard 
wave 
number 
(cm-1) 
Test 
wave 
number 
(cm-1) of 
drug 
Test wave number (cm-1) of 
excipients 
Xanthan 
gum pectin 
Sodium 
alginate 
N-H stretching 3000-3600 3432.67 - - 3420.14 
CH stretching 2700-3300 2964.05 2922.59 2938.02 2922.5 
N-H bending 1500-1700 - 1541.81 1541.81 1542.77 
COOH stretching 1500-1760 1743.33 1618.95 1648.84 1620 
Alkanes(bending) 1340-1470 1429.96 1415 1420 1420 
C-N stretching 1180-1360 1186.97 1317.1 1317 1317.1 
O-H bending 1200-1400 1228.43 1384.64 1345 1384 
C-F stretching 1100-1250 1162.87 1157.0 1159.0 1159.0 
N-H rocking 700-900 816.706 893.84 848.74 842.74 
Mono sub benzene 
ring(rocking) 730-770 754.55 790.69 746.31 746.31 
C-O stretching 1050-1300 1278.57 1058.73 1501 - 
 
 
 
 
 
 
Table 7: IRspectrum of Perindopril with excipients  
(Xanthan gum, sodium alginate, pectin) (Skoog DA et al., 2007) 
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Functional 
group 
assignment 
Standard 
wave 
number 
(cm-1) 
Test 
wave 
number 
(cm-1) 
of drug 
Test wave number (cm-1) of 
excipients 
Drug + 
Xanthan 
Drug 
+SA 
Drug+ 
pectin 
N-H stretching 3000-3600 3432.67 3067.23 3067 3420.14 
CH stretching 2700-3300 2964.05 3026.73 3026.73 2922.5 
N-H bending 1500-1700 - 1498.42 1541.81 1542.77 
COOH stretching 1500-1760 1743.33 1648.95 1648.84 1620 
Alkanes(bending) 1340-1470 1429.96 1415 1420 1420 
C-N stretching 1180-1360 1186.97 1321.1 1317 1317.1 
O-H bending 1200-1400 1228.43 1346.64 1345 1384 
C-F stretching 1100-1250 1162.87 1016.0 1159.0 1159.0 
N-H rocking 700-900 816.706 815 848.74 842.74 
Mono sub 
benzene 
ring(rocking) 
730-770 754.55 750.69 746.31 746.31 
C-O stretching 1050-1300 1278.57 1058.73 1501 - 
 The physical mixture of perindopril and excipients was subjected to FTIR 
to identify any interaction between them. 
 There was no appearance or disappearance of any characteristic peak of 
the drug, which confirms the absence of chemical interaction between drug and 
carrier.  
 Hence the excipients sodium alginate, xanthan gum, pectin which was 
observed to be compatible with perindopril was selected for further development 
of the formulation. 
DRUG EXCIPIENT COMPATABILITY STUDY BY DSC: 
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A sharp exothermic peak was observed of the drug at 127.7°C, 
corresponding to its melting point of the drug.(126°C -128°C). 
 
Figure 10: DSC thermo gram of F13 formulation 
 
EVALUATION OF FILMS 
Surface morphology 
Sample of PMDF prepared by fracturing the films in liquid nitrogen, 
mounted on aluminum stubs, and sputter coated with platinum and surface 
morphology of PMDF was studied by scanning electron microscopy (SEM) with 
magnification of X5000 at 20kv. (JEOL 5400, Tokyo, Japan). 
 
Figure 10: SEM of Mouth dissolving film (a) upper surface and (b) lower surface 
EVALUATION OF FILMS 
Thickness 
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 The thickness of all formulations F1- F15 was found by using digital 
micrometer and the results were shown in the table. 
 
Table 8: Determination of thickness for Different formulations of perindopril 
films (F1-F15) 
Formulation Thickness (µm)± SD 
F1 95±5 
F2 100±5 
F3 102±2.5 
F4 99±3.6 
F5 99±1 
F6 96.6±1.5 
F7 97±2.5 
F8 100±3.5 
F9 97.6±2.5 
F10 102±4 
F11 103±2.6 
F12 98±3.2 
F13 99±2.6 
F14 100±1.3 
F15 95±2 
 
The thickness of F1 to F15 was found to be 48-110µm. From the results 
obtained from the above formulations, all formulations showed thickness of films 
as 5-200µm and complies with the limit as per the previous value. 
 
FOLDING ENDURANCE: (Kaur Mandeep etal., 2013) 
        Three films of each formulation were cut by using sharp blade. Folding 
endurance was determined by repeatedly folding a small strip of film at the same 
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place till it break. The number of times, the film could be folded at the same place 
without breaking gave the value of folding endurance. The mean values of three 
readings were calculated. 
 
Table 9: Determination of folding endurance for Different formulations of 
perindopril films (F1-F15) 
Formulation Folding endurance 
F1 50 
F2 75 
F3 100 
F4 105 
F5 110 
F6 56 
F7 80 
F8 100 
F9 110 
F10 123 
F11 48 
F12 78 
F13 100 
F14 120 
F15 148 
 
    The folding endurance value of F1 to F15 was found to be 48-110. From 
the results obtained from the above formulations, all formulations showed folding 
endurance value complies with in the limit 100-150except F1, F2, F6, F7, F11 and 
F12 fail to complies with the limit as per previous value. 
 
SURFACE PH OF FILMS: (Birari A.E et al., 2014), 
        The surface pH of films was determined to investigate the possible side effect 
because of change in pH in vivo, since an acidic or alkaline pH may cause 
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irritation to oral mucosa. The film to be tested was placed in a test tube and was 
moistened with 1.0 ml of distilled water and kept for 30 second. The pH was 
noted after bringing the electrode of the pH meter in contact with the surface of 
the formulation and allowing equilibrating for 1 min. The average of three 
determinations for each of the formulation was taken and standard deviation was 
also calculated. Surface pH of all films was found to be within the limits 6-7. 
 
Table 10: Determination of Surface pH for Different formulations of 
perindopril films (F1-F15) 
FORMULATION SURFACE pH 
F1 6.14±0.05 
F2 6.25±0.10 
F3 6.35±0.02 
F4 6.5±0.08 
F5 6.45±0.05 
F6 6.65±0.05 
F7 6.73±0.05 
F8 6.82±0.02 
F9 6.75±0.5 
F10 6.77±0.06 
F11 6.8±0.10 
F12 6.7±0.05 
F13 6.9±0.07 
F14 6.5±0.12 
F15 6.85±0.08 
 
 
DISINTEGRATION TEST (USP 2007) 
Disintegration test for all prepared formulations was carried out using 
disintegration test apparatus as prescribed in USP 2007. F1-F15 showed a 
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disintegration time of 7-58minutes. From the results obtained, by increasing the 
concentration of polymer, disintegration time was increased.  
 
Table 11: Determination of disintegration time for different formulations of 
perindopril films (F1-F15) 
Formulation code Disintegration time (seconds) 
F1 7 
F2 12 
F3 23 
F4 28 
F5 40 
F6 10 
F7 12 
F8 20 
F9 24 
F10 35 
F11 5 
F12 9 
F13 15 
F14 25 
F15 33 
 
The disintegration time of F11 was found to be 5 seconds which took less 
time as compared to all other formulations (F1-F15). From the results obtained 
from the above formulations, other thanF5,F10,F15 disintegration time  of all 
films was found to be within the limit as 5-30 seconds as per specification  
(USP 2007). Based on the disintegration time alone, F11 can be lead to develop 
perindopril as fast dissolving delivery system. 
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Figure 12: Determination of disintegration timeof different formulations of 
perindopril fast dissolving films (F1-F15) 
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DRUG CONTENT UNIFORMITY (Velmurugan S et al., 2013) 
Percentage of drug content for different formulations was calculated and 
the results were shown in the table 12. 
 
Table 12: Determination of drug content uniformity for different 
formulations of perindopril mouth dissolving films (F1-F15) 
 
Formulation code Drug content (%) 
F1 86 
F2 90 
F3 100 
F4 102 
F5 104 
F6 87 
F7 92 
F8 99 
F9 113 
F10 104 
F11 85 
F12 98 
F13 106 
F14 97 
F15 90 
  
Percentage of drug content of F9 was found to be 113% and was 
considered as best formulation compared to the other formulation. The 
formulations showed percentage drug content 85-113%. From the results obtained 
from the above formulations. The drug content of films should be complies with 
the limit as 85-110% as per IP specifications (IP 2007).  
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Invitro diffusion studies (Rahul Nair et al.,2012). 
In vitro drug release studies were performed by using Franz diffusion cell 
with dialysis membrane. It consists of a donor compartment and a receptor 
compartment. The receptor compartment was filled with 20ml of phosphate buffer 
solution as a diffusion medium. The prepared film was taken in the receptor 
compartment the medium was continuously stirred at 50 rpm using magnetic 
beads and the temperature was maintained at 37±1˚C. 1ml sample of receptor 
fluid was withdrawn at predetermined intervals and volume was replaced with 
same volume of 1ml phosphate buffer solution the sample analyzed 
spectrophotometrically at 210 nm using JASCO V 530.The cumulative amount of 
drug permitted was calculated and plotted against time. 
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Table 13: Determination of in-vitro diffusion study of different formulations 
of perindopril fast dissolving film (F1-F5) 
Time 
(minutes) 
Cumulative percentage  release of perindopril fast dissolving 
film 
F1 F2 F3 F4 F5 
0 0 0 0 0 0 
2 24 22 27 23 22.5 
4 39 38 37 42 40 
6 44 48 43 46 43 
8 50 58 57 57 53 
10 64 66 70 69 65 
12 78 74 78 78 73 
14 82 89 86 82 80 
16 87 - - 89 85 
    
 
Figure 12: Determination of in-vitro release of 
Different formulations of perindopril fast dissolving film (F1-F5) 
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Table 14: Determination of in-vitro diffusion study of different formulations 
of perindopril fast dissolving film (F6-F10) 
Time 
(minutes) 
Cumulative percentage  release of perindopril  
fast dissolving film 
F6 F7 F8 F9 F10 
0 0 0 0 0 0 
2 15 17 20 22 21 
4 30 33 38 36 37 
6 38 40 43 42 45 
8 52 54 58 55 57 
10 60 63 67 62 66 
12 73 75 78 77 74 
14 75 78 84 87 86 
16 84 87 89 90 91 
 
 
Figure 14: Determination of in-vitro release of 
Different formulations of perindopril fast dissolving film (F6-F10) 
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Table 15: Determination of in-vitro diffusion study of different formulations 
of perindopril dissolving film (F11-F15) 
Time 
(minutes) 
Cumulative percentage  release of perindopril fast dissolving 
films 
F11 F12 F13 F14 F15 
0 0 0 0 0 0 
2 17 24 21 36 29 
4 33 50 39 64 42 
6 41 71 56 82 57 
8 59 82 77 91 69 
10 68 93 89 93 76 
12 79 96 92 96 88.2 
14 84 97 95 97 95.7 
16 92 - 98 - - 
 
 
 
Figure 15: determination of in-vitro release of different formulations of 
perindopril fast dissolving film (F11-F15) 
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Final optimized formulation was subjected to aggravated conditions of 
temperature and relative humidity by wrapping it in aluminium foil and packaging 
it in glass container. The films were kept in stability chamber, at 40 ± 20C 
temperature and 75 ± 5% RH for 3 months. After 3 months the films were tested. 
 
Table 16: Stability Study for Formulation F13 
 
parameter Initial  3 month 
Thickness(mg) 99±2.6 99±3 
Weight variation 47±2 48±1.5 
Folding endurance 103 105 
Disintegration time(sec) 15 16 
Percentage drug content (%) 106 107 
Surface pH 6.9±0.07 6.9±0.2 
 
Table 17:Invitrodiffusion study for optimized formulation 
Time (minutes) Initial After 3 month 
0 0 0 
2 21 22 
4 39 38 
6 56 55 
8 77 75 
10 89 87 
12 92 90 
14 95 94 
16 98 97 
 
 The optimized formulation F13 was evaluated for the stability studies 
which was stored at room temperature (30± 20C);For three months. From the 
evaluation, it was found that there is no significant change in appearance, pH, 
folding endurance, surface pH, drug content, in vitro disintegration time and 
percentage drug diffusion study. 
Kinetic analysis of in-vitro release data 
Results & Discussion 
 
 
 
Department of Pharmaceutics  66 
To analyze the in-vitro release data, various kinetic models, the zero-order, 
the first-order, the Higuchi and the Korsmeyer-Peppas models, were used to 
describe the release kinetics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Drug release kinetics of F1 
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Figure 17: Drugrelease kinetics of F2 
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Figure 18: Drug release kinetics of F3 
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Figure 19:Drug release kinetics of F4 
 
  
Results & Discussion 
 
 
 
Department of Pharmaceutics  70 
 
  
 
  
 
Figure 20: Drug release kinetics of F5 
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Figure 21:Drug release kinetics of F6 
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Figure 22:Drug release kinetics of F7 
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Figure23 :Drug release kinetics of F8 
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Figure24 :Drug release kinetics of F9 
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Figure25 :Drug release kinetics of F10 
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Figure 26:Drug release kinetics of F11 
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Figure 26:Drug release kinetics of F12 
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Figure 27:Drug release kinetics of F13 
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Figure28 :Drug release kinetics of F14 
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Figure 29:Drug release kinetics of F15 
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Table 17: Kinetic analysis of in-vitro drug release 
 data o formulations F1-F15 
Formulation 
code 
Zero order 
R2 
First order 
R2 
Higuchi 
model R2 
Korsemeyer-
peppas 
equation n 
F1 0.9154 0.973 0.965 0.658 
F2 0.941 0.983 0.966 0.690 
F3 0.933 0.975 0.965 0.680 
F4 0.8956 0.987 0.979 0.620 
F5 0.903 0.985 0.977 0.631 
F6 0.966 0.984 0.938 0.771 
F7 0.958 0.984 0.948 0.742 
F8 0.934 0.985 0.964 0.686 
F9 0.951 0.971 0.952 0.725 
F10 0.942 0.983 0.965 0.695 
F11 0.963 0.974 0.940 0.764 
F12 0.833 0.979 0.962 0.578 
F13 0.8737 0.966 0.949 0.634 
F14 0.9109 0.984 0.983 0.629 
F15 0.9109 0.984 0.983 0.629 
 
 In order to determine the release model the in vitro release data were 
analyzed according to zero order, first order and diffusion controlled mechanism 
according to simplified higuchi model. The preference of a certain mechanism 
was based on the coefficient of determination for the parameters studied, where 
the highest coefficient of determination is preferred for the selection of the order 
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of  release. However in many experimental situations the mechanism of drug 
diffusion deviates from the Fickian equation and follows a non-Fickian 
(anomalous) behavior. In the cases the Korsemeyer-peppas model was used to 
analyze the release kinetics.Using the Korsemeyer and Peppas model, n = 0.45 
indicates case I or Fickian diffusion, 0.45 n> 0.89 indicates anomalous behavior or 
non-Fickian transport, n = 0.89 indicates case II transport and n greater than 0.89 
indicates super case II transport. 
         Release of all the formulations followed first order kinetics, exhibited 
diffusion controlled mechanism as indicated from the highest coefficient of 
determination (r2). According to the Korsemeyer-peppas model anomalous (non 
Fickian release) was observed in all formulations as indicated from the release 
exponent which was in the range of 0.57-0.77 for these formulations.  
It was found that the optimized formulation F13 follows first order kinetic model 
as it had highest R2 value with Korsemeyer – Peppas mechanism. The 
“n”exponent value of optimized batch was found to be 0.63. Hence it shows the 
optimized formulation followed non-Fickian diffusion. 
 Summary & Conclusion 
 
 
 
Department of Pharmaceutics 83 
SUMMARY AND CONCLUSION 
Perindopril is a hypertension drug. Hypertension is one of the primary risk 
factors for cardiovascular diseases, including cardiovascular stroke. The absolute 
bioavailability of perindopril is approximately 60-75%. Following absorption, 
perindopril is hydrolyzed to Perindoprilat, which has an average bioavailability of 
20%.  However, food decreases the extent of biotransformation to Perindoprilat 
and reduces its bioavailability by 35%.To overcome the above mentioned 
problems an attempt was made to develop and to improve the solubility of drug 
and reduce side effects, it was attempted to develop fast dissolving films with 
some natural polymer. 
 FTIR spectroscopic studies were carried out in order to establish 
compatibility between drug and carriers. The results were concluded that there 
were no chemical interactions between drug and the carriers used, so they could 
be used for the formulation of perindopril fast dissolving films. 
          DSC studies were carried out for optimized formulation a sharp exothermic 
peak observed at 127°C corresponding to its melting point of the drug. 
(126°C -128°C). The results were concluded that there were no chemical 
interactions between drug and the carriers used. 
 
Around fifteen formulations of perindopril were developed as fast 
dissolving films using various excipients which were found to be compatible 
using FTIR of films. Formulation F1-F15 was perindopril fast dissolving films 
prepared using three different polymers such as sodium alginate, Xanthan gum 
and pectin.  
 Perindopril films were evaluated for quality control tests such as thickness, 
weight variation, folding endurance, SEM, surface pH, disintegration time,  
in-vitro diffusion, drug content, kinetic studies and stability study.  
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           The thickness of all formulations complies with the limit. Weight variation 
of F15 alone does not complies with the standard. The folding endurance of all 
formulation with in the limit 100-150 except F1,F2,F6,F7,F11 and F12 fail to 
complies with the limit as per standard value. Scanning electron micrograph of the 
optimized formulation F13 are shown at a magnification ratio of X5000 at 20kv. 
The surface morphology of the prepared nanoparticles was shown .The surface pH 
of all formulations complies with the limit. The disintegration time of all the 
formulations except F5, F10 and F15 fails to be within the limit. The drug content 
of all the formulations was found be within the limit. The in-vitro drug study of 
F13 was found to give the highest % diffusion than other formulation. From the 
in-vitro diffusion studies of fast dissolving films, it was observed that F13 showed 
more % diffusion at 16 minutes. 
The In vitro data was fit to kinetic models to explain permeation profiles. 
The coefficient of correlation of each of the kinetics was calculated and compared. 
From the Regression coefficient value it was concluded that it follows first order 
kinetics. The data was further treated as per Higuchi’s equation indicated that the 
drug released by diffusion predominated with the formulation and Korsemeyer 
peppas model exponent value n describes n (value 0.45-0.85) shows  
non Fickian iffusion. 
Optimized formulation F13 were found to be stable at accelerated stability 
conditions. 
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CONCLUSION 
 
Perindopril fast dissolving films have been successfully prepared by 
solvent casting method. 
Perindopril is a anti hypertension drug was selected for the preparation of 
fast dissolving films. 
Xanthan gum, sodium alginate and pectin were used as polymers for the 
preparation of perindopril mouth dissolving films. 
Perindopril films were prepared by solvent casting method using Xanthan 
gum, sodium alginate, pectin at 100,150,200,250,300 mg respectively. 
Based on this physiochemical characterization in vitro drug diffusion and 
drug release kinetics of perindopril showed 93.5% of drug at the end of 16th mins. 
 The evaluation test for films of perindopril suggest that it is promising to 
be developed as fast dissolving films with above mentioned excipients which can 
enhance the diffusion, thereby the release and hence the bioavailability may be 
effected and may have impact on its bioavailability. 
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